运动对阿尔茨海默氏病模型中来自大脑的神经营养因子的影响:系统性审查和元分析
Shiyan Zhang1, Boya Gu2, Kai Zhen3
1Beijing Key Laboratory of Sports Performance and Skill Assessment, Beijing Sport University, Beijing, China; Department of Strength and Conditioning Assessment and Monitoring, Beijing Sport University, Beijing, China.
Archives of gerontology and geriatrics
|June 15, 2024
概括
在阿尔茨海默氏病 (AD) 模型中,运动显著增强了来自大脑的神经营养因子 (BDNF). 特定的运动类型,如游泳和跑步机跑步,显示出最有希望的增加大脑BDNF水平.
科学领域:
- 神经科学是一个神经科学.
- 运动生理学 运动生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在阿尔茨海默氏病 (AD) 模型中,关于运动对来自大脑的神经营养因子 (BDNF) 的影响存在相互矛盾的发现.
- 研究设计的变化,包括性别,年龄,疾病严重程度和干预类型,导致结果不一致.
- 需要进行系统审查,以巩固AD模型中运动和BDNF的证据.
研究的目的:
- 在阿尔茨海默氏病 (AD) 模型中系统地评估目前关于运动对BDNF水平影响的证据.
- 确定在调节BDNF方面最有效的特定运动干预措施.
- 分析运动对ADDNF在AD受影响的不同大脑区域的影响.
主要方法:
- 在PubMed,Web of Science,Cochrane和EBSCO数据库中进行了全面的文献搜索,截至2023年7月20日.
- 包括的研究是随机对照试验 (RCT),调查AD模型中的运动干预措施,结果为BDNF.
- 来自36项符合条件的研究的数据进行了元分析,以确定运动对BDNF水平的整体影响大小 (SMD).
主要成果:
- 运动在AD模型中增加BDNF水平方面显示出显著的整体效应 (SMD = 0.98,P < 0.00001).
- 跑步机炼 (SMD = 0.92),游泳 (SMD = 1.79) 和自愿轮跑 (SMD = 0.51) 都有效提高了BDNF.
- 运动在海马体 (SMD = 0.92) 和皮质 (SMD = 1.56) 中显著增加了BDNF,游泳显示出最大的有效性.
结论:
- 运动干预措施,特别是跑步机运动,游泳和自愿的轮子运行,在AD模型中显著提高了BDNF水平.
- 游泳成为增加AD模型海马体和皮质BDNF的最有效的运动方式.
- 这些发现支持特定运动方案的治疗潜力,通过调节BDNF来管理AD.
更多相关视频
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
2.5K
05:04Application of Passive Head Motion to Generate Defined Accelerations at the Heads of Rodents
Published on: July 21, 2022
1.7K
相关概念视频
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
